The Application of Nanobody in CAR-T Therapy

Применение нанотел в терапии CAR-T
Ruining Zhang, Chaolemeng Bao, Quanli Gao, Linlin Li, Lu Han, Bingxiang Zhang, Yijin Ding, Zongpei Song, Jishuai Zhang, Xian-Hui Wu
2021-02-08

BCMA-targeted CAR-TCAR-NK cellsantigen-binding domainchimeric antigen receptornanobody-based CAR-T
Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks.
1
Nanobodies are suitable CAR antigen-binding domains because of their small size, high stability, affinity, and manufacturing feasibility.
2
Nanobody applications in CAR therapy have progressed from laboratory studies to clinical evaluation and may support advanced CAR-T designs for challenging targets.
3
Nanobody-based CAR designs have demonstrated functionality against more than ten tumor-specific targets.
4
Nanobody-based CAR-T and CAR-NK cells show antitumor activity in vitro and in vivo after expression in multiple immune-cell types.
5
Single-nanobody and bivalent-nanobody anti-BCMA CAR-T cells produce clinical effects comparable to scFv-based CAR-T cells.

nanobody-based chimeric antigen receptor immune cells (CAR-T and CAR-NK) targeting tumors

the anti-tumor efficacy and therapeutic potential of nanobody-based CAR constructs, including their target binding, stability, and clinical performance

Publication Details
Publication Date
2021-02-08
Journal
Publisher
ISSN
Cited by
112
Access Type
Author Information
Authors
Ruining Zhang
Chaolemeng Bao
Quanli Gao
Linlin Li
Lu Han
Bingxiang Zhang
Yijin Ding
Zongpei Song
Jishuai Zhang
Xian-Hui Wu
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%